The Amplimetrix Serum Profiling Assay measures patient serum antibodies against proprietary panels of tumor-specific antigens. Measuring the patient’s baseline and post-treatment anti-tumor immune response is pivotal for successful clinical development of novel cancer therapies. Baseline measurements correlated to clinical outcome may help identify responder patients. Drugs that induce a broad-based immune response in the days and weeks following administration are more likely to meet the clinical end-points required for development and regulatory approval.